{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:16:12Z","timestamp":1753892172700,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The combination of pembrolizumab and chemotherapy has demonstrated notable clinical advantages in improving overall survival than chemotherapy alone for patients with untreated advanced pleural mesothelioma. The purpose of this study was to assess its cost-effectiveness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A Markov state-transition model was constructed using data from the IND227 phase 3 randomized clinical trial. Utility values for health states were taken from the IND227 trial, and direct medical costs were from the pertinent literature and local pricing data. Outcomes measured included quality-adjusted life years (QALYs), incremental cost-effectiveness ratio (ICER), incremental net health benefit (INHB), and incremental net monetary benefit (INMB). To manage the uncertainty in the model, both probabilistic sensitivity analysis (PSA) and one-way sensitivity analysis (OWSA) were used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the base-case analysis, pembrolizumab plus chemotherapy resulted in an incremental gain of 0.23 QALYs at an additional cost of $18,199.63, resulting in an ICER of $80,557.23\/QALY. This was not favorable compared to China\u2019s willingness-to-pay (WTP) threshold of $38,042.49\/QALY, with an INHB of \u22120.25 QALYs and an INMB of $-9,605.00. Subgroup analyses showed ICERs for pembrolizumab plus chemotherapy versus chemotherapy of $33,917.61 and $99,536.73 in non-epithelioid and epithelioid patients, respectively. PSA indicated probabilities of cost-effectiveness for pembrolizumab plus chemotherapy at 0.55%, 69.41%, and 0.14% for the entire population and the non-epithelioid and epithelioid subgroups, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the Chinese healthcare system, the combination of pembrolizumab and chemotherapy did not prove to be more cost-effective than chemotherapy alone as an initial treatment for untreated advanced pleural mesothelioma, with the exception of patients who have non-epithelioid histology.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1402423","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:34:40Z","timestamp":1736228080000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system"],"prefix":"10.3389","volume":"15","author":[{"given":"Wenwang","family":"Lang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changchun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuyong","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/s0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s40273-023-01305-3","article-title":"Cost effectiveness and budget impact of nivolumab plus ipilimumab versus platinum plus pemetrexed (with and without bevacizumab) in patients with unresectable malignant pleural mesothelioma in Switzerland","volume":"41","author":"Barbier","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays","volume":"87","author":"Chapel","year":"2019","journal-title":"Hum. Pathol."},{"key":"B4","unstructured":"China pharmacoeconomic evaluation guideline 2020 (Draft for comments)\n          \n          \n          2024"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/s0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/s1470-2045(21)00471-x","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40273-024-01399-3","article-title":"A systematic review of modeling approaches to evaluate treatments for relapsed refractory multiple myeloma: critical review and considerations for future health economic models","volume":"42","author":"Freitag","year":"2024","journal-title":"Pharmacoeconomics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"B10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11096-023-01662-1","article-title":"Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma","volume":"46","author":"Lang","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"619376","DOI":"10.3389\/fonc.2021.619376","article-title":"Comprehensive comparison between adjuvant targeted therapy and chemotherapy for EGFR-mutant nsclc patients: a cost-effectiveness analysis","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"8219","DOI":"10.2147\/cmar.S335515","article-title":"Cost-effectiveness analysis of camrelizumab immunotherapy versus docetaxel or irinotecan chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma","volume":"13","author":"Lin","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1092385","DOI":"10.3389\/fimmu.2023.1092385","article-title":"Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma","volume":"14","author":"Liu","year":"","journal-title":"Front. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1172242","DOI":"10.3389\/fimmu.2023.1172242","article-title":"Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China","volume":"14","author":"Liu","year":"","journal-title":"Front. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/jto.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/bjs.9501","article-title":"Cost-effectiveness of early laparoscopic cholecystectomy for mild acute gallstone pancreatitis","volume":"101","author":"Morris","year":"2014","journal-title":"Br. J. Surg."},{"key":"B17","unstructured":"Clinical practice guidelines in Oncology: mesothelioma pleural\n          \n          \n          2024"},{"key":"B18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"33","author":"Popat","year":"2022","journal-title":"Ann. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1204722","DOI":"10.3389\/fonc.2023.1204722","article-title":"Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies","volume":"13","author":"Sahu","year":"2023","journal-title":"Front. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2022.03.012","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743","volume":"167","author":"Scherpereel","year":"2022","journal-title":"Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"851522","DOI":"10.3389\/fonc.2022.851522","article-title":"Cost-effectiveness of nivolumab plus chemotherapy vs. Chemotherapy as first-line treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophagel adenocarcinoma in China","volume":"12","author":"Shu","year":"2022","journal-title":"Front. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/jco.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1111\/1759-7714.15022","article-title":"Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma","volume":"14","author":"Wang","year":"2023","journal-title":"Thorac. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"10684","DOI":"10.3390\/ijms241310684","article-title":"Investigation of molecular interactions mechanism of pembrolizumab and PD-1","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e70405","DOI":"10.1002\/cam4.70405","article-title":"Cost-effectiveness analysis of adjuvant alectinib versus platinum-based chemotherapy in resected ALK-positive non-small-cell lung cancer in the Chinese health care system","volume":"13","author":"Wei","year":"2024","journal-title":"Cancer Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1186\/1471-2407-14-984","article-title":"Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy","volume":"14","author":"Wu","year":"2014","journal-title":"BMC Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3389\/fonc.2020.01336","article-title":"Cost-effectiveness of tucatinib in human epidermal growth factor receptor 2-positive metastatic breast cancer from the US and Chinese perspectives","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"924126","DOI":"10.3389\/fphar.2022.924126","article-title":"Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer","volume":"13","author":"Yang","year":"","journal-title":"Front. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"17588359221116604","DOI":"10.1177\/17588359221116604","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma","volume":"14","author":"Yang","year":"","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s13023-023-02925-w","article-title":"First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis","volume":"18","author":"Yang","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"947375","DOI":"10.3389\/fpubh.2022.947375","article-title":"Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma","volume":"10","author":"Ye","year":"2022","journal-title":"Front. Public Health"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.05.012","article-title":"Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial","volume":"110","author":"Zhan","year":"2017","journal-title":"Lung Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.breast.2022.10.010","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: a cost-effectiveness analysis","volume":"66","author":"Zhu","year":"2022","journal-title":"Breast"},{"key":"B37","doi-asserted-by":"publisher","first-page":"17562848231207200","DOI":"10.1177\/17562848231207200","article-title":"Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric\/gastroesophageal junction cancer: a cost-effectiveness analysis","volume":"16","author":"Zhu","year":"2023","journal-title":"Ther. Adv. Gastroenterol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1402423\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:34:45Z","timestamp":1736228085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1402423\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":37,"alternative-id":["10.3389\/fphar.2024.1402423"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1402423","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1402423"}}